Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data

被引:11
|
作者
Jin, Jie [1 ]
Wu, Depei [2 ]
Liu, Yang [3 ]
Pan, Sisi [3 ]
Yan, Jean Li [4 ]
Aram, Jalal A. [4 ]
Lou, Yin-jun [1 ]
Meng, Haitao [1 ]
Chen, Xiaochen [1 ]
Zhang, Xian'an [3 ]
Schwartz, Ilan S. [5 ,6 ]
Patterson, Thomas F. [6 ,7 ]
机构
[1] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Hematol, Hangzhou, Zhejiang, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China
[3] Pfizer Inc, Beijing, Peoples R China
[4] Pfizer Inc, New York, NY USA
[5] Univ Alberta, Dept Med, Div Infect Dis, Edmonton, AB, Canada
[6] UT Hlth Sci San Antonio, Div Infect Dis, San Antonio, TX USA
[7] South Texas Vet Hlth Care Syst, San Antonio, TX USA
关键词
Invasive aspergillosis; Computed tomography scans; Diagnosis; Radiographic abnormalities; Antifungal treatment; Hematopoietic stem cell transplant; Hematologic malignancy; PREEMPTIVE ANTIFUNGAL THERAPY; PULMONARY ASPERGILLOSIS; TRANSPLANT RECIPIENTS; NEUTROPENIC PATIENTS; COMPUTED-TOMOGRAPHY; FUNGAL-INFECTIONS; HALO SIGN; HIGH-RISK; DIAGNOSIS; MANAGEMENT;
D O I
10.1186/s12879-019-4039-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundPulmonary computed tomography (CT) scans are commonly used as part of the clinical criteria in diagnostic workup of invasive fungal diseases like invasive aspergillosis, and may identify radiographic abnormalities, such as halo signs or air-crescent signs. We assessed the diagnostic utility of CT assessment in patients with hematologic malignancies or those who had undergone allogeneic hematopoietic stem cell transplantation in whom invasive aspergillosis was suspected.MethodsThis post-hoc analysis assessed data from a prospective, multicenter, international trial of voriconazole (with and without anidulafungin) in patients with suspected invasive aspergillosis (IA; proven, probable, or possible, using 2008 European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria) [NCT00531479]. Eligible patients received at least one baseline lung CT scan.ResultsOf 395 patients included in this post-hoc analysis, 240 patients (60.8%) had confirmed' proven (9/240, 3.8%) or probable (231/240, 96.3%) invasive aspergillosis (cIA) and 155 patients (39.2%) had non-confirmed' invasive aspergillosis (all nIA; all possible IA (de Pauw et al., Clin Infect Dis 46:1813-21, 2008)). Mean age was 52.3 and 50.5years, 56.3 and 60.0% of patients were male, and most patients were white (71.7 and 71.0%) in the cIA and nIA populations, respectively. Median baseline galactomannan was 1.4 (cIA) and 0.2 (nIA), mean Karnofsky score was 65.3 (cIA) and 66.8 (nIA), and mean baseline platelet count was 48.0 (cIA) and 314.1 (nIA). Pulmonary nodules (46.8% of all patients), bilateral lung lesions (37.5%), unilateral lung lesions (28.4%), and consolidation (24.8%) were the most common radiographic abnormalities. Ground-glass attenuation (cIA: 24.2%; nIA: 11.6%; P<0.01) and pulmonary nodules (cIA: 52.5%; nIA: 38.1%; P<0.01) were associated with cIA. Other chest CT scan abnormalities (including halo signs and air-crescent signs) at baseline in patients with hematologic malignancy or hematopoietic stem cell transplantation, and suspected IA, were not associated with cIA.ConclusionsThese findings highlight the limitations in the sensitivity of chest CT scans for the diagnosis of IA, and reinforce the importance of incorporating other available clinical data to guide management decisions on individual patients, including whether empirical treatment is reasonable, pending full evaluation.Trial registrationNCT00531479 (First posted on ClinicalTrials.gov on September 18, 2007)
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data
    Jie Jin
    Depei Wu
    Yang Liu
    Sisi Pan
    Jean Li Yan
    Jalal A. Aram
    Yin-jun Lou
    Haitao Meng
    Xiaochen Chen
    Xian’an Zhang
    Ilan S. Schwartz
    Thomas F. Patterson
    BMC Infectious Diseases, 19
  • [2] Post-hoc data analysis: benefits and limitations
    Curran-Everett, Douglas
    Milgrom, Henry
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2013, 13 (03) : 223 - 224
  • [3] Anamorelin in Cachectic Patients with Advanced NSCLC, a Post-Hoc Pooled Efficacy Data Analysis of Two Phase 3 Trials
    Currow, David
    Teme, Jennifer
    Abernethy, Amy
    Friend, John
    Fearons, Kenneth
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S665 - S666
  • [4] TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS AND METABOLIC SYNDROME: A POST-HOC ANALYSIS OF PHASE 3 STUDIES
    Ritchlin, C.
    Giles, J.
    Ogdie, A.
    Gomez-Reino, J.
    Stockert, L.
    Young, P.
    Wang, C.
    Romero, A. B.
    Kudlacz, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1023 - 1023
  • [5] Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data
    Rolfo, C.
    Gerber, D. E.
    Kotecha, R.
    Ward, J.
    Akerley, W.
    Naveh, A.
    Shapira, N.
    Leal, T.
    Langer, C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S188 - S188
  • [6] Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial
    Kontoyiannis, Dimitrios P.
    Selleslag, Dominik
    Mullane, Kathleen
    Cornely, Oliver A.
    Hope, William
    Lortholary, Olivier
    Croos-Dabrera, Rodney
    Lademacher, Christopher
    Engelhardt, Marc
    Patterson, Thomas F.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018, 73 (03) : 757 - 763
  • [7] Improvement in Function After Lasmiditan Treatment: Post-Hoc Analysis of Pooled Data From Phase 3 Studies
    Smith, T. R.
    Hake, A.
    Nery, E.
    Rathmann, S.
    Matthews, B.
    Dowsett, S.
    Doty, E.
    HEADACHE, 2020, 60 : 109 - 110
  • [8] Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data
    Francois, Clement
    Hauser, Robert A.
    Aballea, Samuel
    Dorey, Julie
    Kharitonova, Elizaveta
    Hewitt, L. Arthur
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 515 - 525
  • [9] Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase, 3 clinical trial
    Murphy, D.
    Wooton, P.
    Jacob, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I415 - I416
  • [10] Relationship between haemoglobin status and utility in patients with iron deficiency anaemia in inflammatory bowel disease: A post-hoc analysis of a phase, 3 clinical trial
    Murphy, D.
    Wooton, P.
    Jacob, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I415 - I416